Treatment decisions on the most appropriate choice will have to be balanced across a number of factors including assessment on the extent of tumor PD-L1 expression, patient co-morbidities, patient performance status, extent of disease as well as patient preference. This evidence concerns the gene CD274 and neoplasm.